MacroGenics discovers, develops, and delivers biologic for the treatment of cancer, autoimmune disorders, and infectious diseases.Read more
MacroGenics's revenue is the ranked 8th among it's top 10 competitors. The top 10 competitors average 10.1B. Over the last four quarters, MacroGenics's revenue has grown by 68.5%. Specifically, in Q2 2021's revenue was $30.8M; in Q1 2021, it was $16.9M; in Q4 2020, it was $52.7M; in Q3 2020, MacroGenics's revenue was $18.3M.
No recent acquisitions found related to MacroGenics
No recent investments found related to MacroGenics